Comparison · NCT04960202-sae
PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: serious adverse events. Trial comparisons, record NCT04960202-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04960202-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0183 | 0.0117 | 0.0284 | wilson | |
| Risk in group 2 | 0.0684 | 0.0546 | 0.0852 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0501 | -0.0682 | -0.033 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.268 | 0.163 | 0.441 | log | |
| Odds ratio, group 1 over group 2 | 0.254 | 0.152 | 0.424 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on PF-07321332 300 mg + Ritonavir 100 mg than on Placebo | 20 | 14.7 | 30.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PF-07321332 300 mg + Ritonavir 100 mg | Participants with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received 300 milligrams (mg) PF-07321332 coadministered with 100 mg ritonavir orally, q12h for 5 days. Participants were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24. | 19 | 1,038 | EG000 |
| Group 2 | Placebo | Participants with SARS-CoV-2 infection received placebo orally, q12h for 5 days. Participants were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24. | 72 | 1,053 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From start of study intervention at Day 1 up to end of long-term safety follow-up (Week 24)
Source ClinicalTrials.gov
Trial
- Title
- EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
- NCT number
- NCT04960202
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19
- Interventions
- PF-07321332, Ritonavir, Placebo
- Lead sponsor
- Pfizer
- Results first posted
- 2023-02-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04960202?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04960202-sae